Cardiac fibroblasts are among the most abundant cells in the human heart, yet for decades they were dismissed as passive structural filler between the muscle cells that do the pumping. That picture has changed dramatically. Researchers now know these cells actively maintain the heart’s scaffolding, relay signals to and from muscle cells, orchestrate wound healing after injury, and, when their behavior goes awry, drive the scarring process called fibrosis that underlies many forms of heart failure and dangerous rhythm disturbances. Understanding what cardiac fibroblasts do when things go right, and what tips them toward harm, has become one of the most active frontiers in cardiovascular research.
What Cardiac Fibroblasts Actually Do in a Healthy Heart
In a heart that is working normally, cardiac fibroblasts serve as the maintenance crew for the extracellular matrix, the mesh of proteins (mainly collagens and fibronectin) that gives the heart its shape and mechanical resilience. They continuously produce, remodel, and break down this scaffolding so it stays supple enough for the heart to fill with blood yet strong enough to withstand the pressures of each contraction. Fibroblasts sense the mechanical environment around them, including stretch and tissue stiffness, and adjust their output of matrix proteins accordingly.
This mechanical sensing ability is a double-edged sword. In a healthy heart, it keeps the scaffolding in balance. But when disease increases the mechanical load, the same sensing pathways push fibroblasts toward overproduction of collagen, a theme that surfaces repeatedly in heart disease.
Talking to the Muscle Cells
Cardiac fibroblasts do not sit in isolation. They communicate with the heart’s muscle cells, called cardiomyocytes, in at least three ways, and this crosstalk matters for both normal rhythm and disease.
The most direct route is electrical coupling through gap junctions, tiny protein channels that allow ions to flow between touching cells. In lab cultures, fibroblasts and cardiomyocytes form these connections readily and can synchronize their electrical activity over distances up to about 300 micrometers, with measurable propagation delays that depend on the length of the fibroblast bridge.
1PubMed. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin Whether the same coupling happens inside a living heart is still debated. Indirect evidence suggests it does, but direct proof has been hard to obtain.2PubMed Central. Fibroblast-myocyte coupling in the heart: Potential relevance for therapeutic interventions
A second route is paracrine signaling, where fibroblasts release molecules that drift over to nearby cardiomyocytes and alter their behavior. When fibroblasts detect damaged heart tissue, they secrete factors like interleukin-6 that can trigger cardiomyocyte hypertrophy, the thickening of individual muscle cells that often precedes heart failure.3PubMed Central. Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism A third route involves exosomes, tiny membrane-bound packages that fibroblasts shed into the surrounding fluid. These exosomes carry small RNA molecules and, when delivered to cardiomyocytes, can trigger hypertrophy on their own. Strikingly, depleting the exosomes from fibroblast-conditioned fluid completely abolished the pro-hypertrophic effect in one set of experiments.4JCI Insight. Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy
From Quiet Fibroblast to Aggressive Myofibroblast
The transformation that causes the most trouble in heart disease is fibroblast activation. When fibroblasts encounter injury signals, they shift into a more aggressive state and become myofibroblasts, cells that produce far more collagen and other matrix proteins. The single most important molecular driver of this shift is a signaling molecule called TGF-β. When TGF-β binds its receptor on a fibroblast’s surface, it sets off a cascade of internal signals that flip on genes for collagen production and cell proliferation.5PubMed Central. Pivotal Role of TGF-β/Smad Signaling in Cardiac Fibrosis: Non-coding RNAs as Effectual Players
Tissue stiffness also influences this transition. Stiffer tissue nudges fibroblasts toward myofibroblast behavior. However, experiments with human cardiac fibroblasts showed that TGF-β ultimately overrides stiffness as the dominant regulator. Even in rigid environments, blocking TGF-β signaling could blunt the shift, which suggests that targeting TGF-β pathways may be therapeutic even after significant stiffening has occurred.6PubMed Central. TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts A large-scale computational model of fibroblast signaling confirmed this interplay, correctly predicting about 80 percent of experimentally observed outcomes and identifying cross-talk between TGF-β and mechanical signaling as a key regulatory node.7PubMed Central. A computational model of cardiac fibroblast signaling predicts context-dependent drivers of myofibroblast differentiation
What Happens After a Heart Attack
A heart attack, or myocardial infarction, kills a patch of muscle cells. The heart cannot regenerate that muscle in any meaningful way, so it has to patch the wound with scar tissue, and cardiac fibroblasts run the operation. In the infarct zone, fibroblasts proliferate, convert to myofibroblasts, and deposit large quantities of matrix proteins to maintain the structural integrity of the damaged wall.8PubMed Central. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
This healing process is not a single event but a carefully choreographed sequence. Fibroblasts cycle through distinct polarization states that mirror the broader wound environment: first a pro-inflammatory phase, then an anti-inflammatory phase, and finally a scar-producing reparative phase.9PubMed Central. Emerging Role of Macrophage-Fibroblast Interactions in Cardiac Homeostasis and Remodeling Throughout this transition, macrophages (a type of immune cell) and fibroblasts engage in extensive two-way communication. Macrophages can push fibroblasts toward or away from activation depending on which macrophage subsets are present, and fibroblasts can influence macrophage behavior in return.10PubMed Central. The Macrophage-Fibroblast Dipole in the Context of Cardiac Repair and Fibrosis
The scar that forms after a heart attack is called replacement fibrosis. It sits in the spot where the dead muscle used to be. This type of fibrosis is, in principle, beneficial — without it the wall would rupture. The danger comes when the scarring process fails to shut off or spreads beyond the injury zone.
When Scarring Becomes the Disease
Replacement fibrosis after a heart attack is one thing. Reactive fibrosis, the slow, diffuse collagen accumulation that occurs in chronically overloaded hearts, is another beast entirely. In conditions like long-standing high blood pressure or valve disease, the heart endures sustained pressure overload. Fibroblasts respond by gradually depositing collagen between and around muscle cells and blood vessels throughout the ventricle.11PubMed Central. Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target Unlike the localized scar after a heart attack, this reactive fibrosis is diffuse, making the entire heart wall stiffer and less able to relax.
That stiffness is a major reason why the heart loses its ability to fill properly, a hallmark of heart failure with preserved ejection fraction, or HFpEF. Imaging studies using cardiac MRI have confirmed that patients with HFpEF show measurably higher extracellular volume fractions, an indicator of diffuse fibrosis, and that this increase correlates with worse diastolic filling.12PubMed. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF Advanced single-cell sequencing has revealed that different clusters of fibroblasts are responsible for the two fibrotic patterns in HFpEF: some clusters drive diffuse interstitial fibrosis while distinct clusters generate focal deposits around blood vessels.13PubMed. Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction
Fibrosis and Dangerous Heart Rhythms
Scar tissue does not conduct electricity the way living muscle does. When patches of fibrosis interrupt the normal electrical wiring of the heart, the consequences can be life-threatening. Fibrosis disrupts the orderly wave of electrical activity that makes the heart squeeze in a coordinated fashion. Collagen deposits can force the electrical signal to zigzag around obstacles, slow down, or circle back on itself, creating the conditions for reentrant arrhythmias, where the electrical impulse gets trapped in a loop and drives the heart to beat chaotically.14PubMed Central. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils
Fibrosis also promotes triggered activity, including early afterdepolarizations, abnormal extra electrical impulses that can initiate dangerous rhythms.15PubMed Central. Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy? Computational models show that the picture is complicated by the electrical coupling between fibroblasts and muscle cells described earlier. When fibroblasts are connected to cardiomyocytes, they slightly raise the muscle cell’s resting electrical potential. At low fibroblast density this can actually speed conduction, but as fibroblast content increases, conduction slows and eventually fails. The raised resting potential also extends the refractory period of nearby muscle cells, making reentry easier to trigger with a mistimed beat.16PubMed Central. Effects of fibroblast-myocyte coupling on cardiac conduction and vulnerability to reentry: A computational study The upshot is that fibrosis promotes arrhythmias through multiple overlapping mechanisms, making it a double threat to both the heart’s pumping function and its electrical stability.
Not All Fibroblasts Are the Same
One of the biggest recent shifts in the field has come from single-cell RNA sequencing, a technology that lets researchers read the gene activity of thousands of individual cells at once. The results have shattered the idea that cardiac fibroblasts are a uniform population. They are strikingly heterogeneous, with multiple subpopulations that differ in gene expression, behavior, and location within the heart.
After a heart attack in mice, a distinctive subpopulation emerges that expresses high levels of a protein called CTHRC1. These cells localize to the scar, display an aggressive pro-fibrotic signature, and appear to be essential for wound integrity. When CTHRC1 was absent, animals died at high rates from ventricular rupture. A similar population was later identified in pig hearts and in human heart tissue from patients with infarction and dilated cardiomyopathy.17PubMed Central. Single-cell RNA-seq analysis reveals a crucial role for Collagen Triple Helix Repeat Containing 1 (CTHRC1) cardiac fibroblasts after myocardial infarction Another study identified a highly proliferative fibroblast cluster defined by the marker Postn, which appeared early in the trajectory of fibrosis development and scored high on fibrosis signatures.18PubMed Central. Single-cell RNA sequencing reveals the potential role of Postn(+) fibroblasts in promoting the progression of myocardial fibrosis after myocardial infarction
In dilated cardiomyopathy, a condition where the heart chambers enlarge and weaken, single-cell analysis of human tissue found that the fibroblast population showed the most dramatic gene expression changes of any cell type.19PubMed Central. Single-Cell RNA Sequencing Reveals Cardiac Fibroblast-Specific Transcriptomic Changes in Dilated Cardiomyopathy This finding reinforces the idea that fibroblasts are not passive bystanders in heart disease but central actors whose shifting identities may determine whether disease progresses or stabilizes.
Sex Differences in Cardiac Fibrosis
Women generally develop less cardiac fibrosis than men, a pattern seen in both clinical observations and animal experiments. Part of the explanation involves estrogen. The hormone 17β-estradiol acts through estrogen receptors on cardiac fibroblasts to regulate genes involved in the fibrotic response and the transition to myofibroblasts.20PubMed. Connecting sex differences, estrogen signaling, and microRNAs in cardiac fibrosis
But hormones are not the whole story. In a rat model of chronic stress-hormone stimulation, males developed fibrosis while females did not, and this difference persisted even after the animals’ gonads were removed, eliminating the primary hormone source. The sex difference appeared to be built into the fibroblasts themselves: male fibroblasts were more readily activated to myofibroblasts and had higher activity in a key signaling enzyme, whereas female fibroblasts actually downregulated the relevant receptors under the same stress.21PubMed Central. Cardiac Fibroblasts Mediate a Sexually Dimorphic Fibrotic Response to β-Adrenergic Stimulation Further complicating the picture, estradiol lowered collagen production in female rat and human fibroblasts but actually increased it in male cells, suggesting that the same hormone acts through different receptor subtypes depending on the sex of the cell.22Cardiovascular Research. Sex-specific regulation of collagen I and III expression by 17β-Estradiol in cardiac fibroblasts: role of estrogen receptors
These findings have real clinical implications. Heart failure with preserved ejection fraction is more common in older women, often after menopause when estrogen levels decline. Understanding how sex-specific fibroblast biology interacts with aging could eventually lead to therapies tailored differently for men and women.
Aging, Senescence, and the Fibroblast
As fibroblasts age, some enter a state called cellular senescence, where they stop dividing but remain metabolically active and secrete a cocktail of inflammatory molecules. In the immediate aftermath of a heart attack, this senescent state may actually be helpful: fibroblasts that stop proliferating limit the amount of scar tissue produced. But in chronic conditions, senescent fibroblasts become a problem. Their persistent secretion of inflammatory signals like interleukin-6 fuels ongoing fibrosis and inflammation.23PLOS ONE. Senescent Cardiac Fibroblast Is Critical for Cardiac Fibrosis after Myocardial Infarction
The dual nature of senescence, protective in acute injury but harmful in chronic disease, has made it a tricky therapeutic target. Some researchers are exploring “senolytic” drugs that selectively clear senescent cells, but the timing would matter enormously: clearing them too early after a heart attack could worsen the wound, while clearing them in a chronically fibrotic heart might reduce ongoing damage.24Cardiovascular Research. Senescence mechanisms and targets in the heart
Why Current Drugs Fall Short
Standard heart failure medications like ACE inhibitors and aldosterone blockers, which target the renin-angiotensin-aldosterone system, do reduce fibrosis to some degree. But fibrosis persists in many heart failure patients even on optimal medical therapy, which tells us these drugs are not addressing the full range of pro-fibrotic signals.25PubMed Central. A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease Part of the reason may be that activated fibroblasts undergo metabolic changes that current drugs do not target. When stimulated by TGF-β, cardiac fibroblasts ramp up glycolysis, the quick-and-dirty sugar-burning pathway, increasing acid production and lactate levels. A glycolytic enzyme called PFKFB3 was found to be upregulated both in TGF-β-treated fibroblasts and in the hearts of mice after infarction.26PubMed Central. Upregulation of glycolytic enzyme PFKFB3 by deubiquitinase OTUD4 promotes cardiac fibrosis post myocardial infarction Blocking this metabolic shift could, in theory, starve the fibrotic machinery of energy without harming normal heart function. That idea is early-stage, but it illustrates how deeply fibroblast biology needs to be understood before we can design truly effective anti-fibrotic drugs.
Engineering T Cells to Hunt Fibroblasts
Perhaps the most eye-catching therapeutic idea to emerge in recent years borrows a page from cancer treatment: chimeric antigen receptor (CAR) T cells engineered to seek out and destroy activated cardiac fibroblasts. The concept is straightforward: activated fibroblasts display a surface protein called fibroblast activation protein (FAP) that resting fibroblasts and healthy cardiomyocytes do not. If you arm T cells with a receptor that recognizes FAP, those T cells should hunt down and kill the fibrosis-producing cells while leaving the rest of the heart alone.
In mice, adoptive transfer of FAP-targeting CAR T cells significantly reduced cardiac fibrosis and restored heart function after injury.27PubMed Central. Targeting cardiac fibrosis with engineered T cells A further refinement avoids the complexity and cost of manufacturing CAR T cells outside the body. Instead, modified mRNA encoding the CAR is packaged into lipid nanoparticles that target the patient’s own T cells when injected. In a mouse model of heart failure, this approach produced transient CAR T cells that reduced fibrosis and improved cardiac function.28PubMed Central. CAR T cells produced in vivo to treat cardiac injury In mouse models of myocarditis, FAP-targeting CAR T cells cut fibrosis by more than half and restored ejection fraction above 65 percent.29PubMed Central. Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis
The transient nature of the mRNA-based approach is actually a feature, not a bug. You want enough CAR T cell activity to clear existing activated fibroblasts, but you do not want a permanent anti-fibroblast army patrolling the heart indefinitely, since fibroblasts are essential for normal maintenance and acute wound repair. Human trials have not yet begun, but the pace of preclinical work has been remarkable.
Turning Fibroblasts Into Muscle Cells
An even more ambitious idea takes advantage of a basic biological fact: the adult heart has many fibroblasts and very few dividing muscle cells. What if you could convert the fibroblasts directly into new cardiomyocytes? In 2010, researchers showed that delivering three transcription factors (Gata4, Mef2c, and Tbx5) to mouse fibroblasts could reprogram them into cells that expressed cardiac muscle markers, displayed cardiomyocyte-like gene profiles, and contracted spontaneously. Fibroblasts injected into mouse hearts after transduction with these factors also differentiated into cardiomyocyte-like cells in vivo.30Cell. Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors
Since then, multiple independent labs have confirmed that in vivo cardiac reprogramming improves heart function and reduces fibrosis after myocardial infarction in animal models.31PubMed Central. Fibroblast Reprogramming in Cardiac Repair The appeal is clear: rather than trying to limit the damage fibroblasts cause, you turn the culprits into replacements for the muscle cells that were lost. But efficiency remains low, the reprogrammed cells are not yet fully identical to native cardiomyocytes, and the transition from mouse studies to human hearts involves enormous technical hurdles. Still, the concept represents a fundamentally different approach to heart repair, one where the fibroblast’s abundance becomes an asset rather than a liability.
Epigenetic Switches Behind Activation
Understanding why some fibroblasts activate and others do not has increasingly pointed toward epigenetics, the chemical modifications that sit on top of DNA and histones and control which genes are turned on or off without changing the genetic code itself. Three main categories of epigenetic regulation have been implicated in cardiac fibroblast activation: modifications to DNA itself, modifications to the histone proteins that DNA wraps around, and the activity of non-coding RNAs, short stretches of genetic material that do not make proteins but instead regulate gene expression.32PubMed Central. Roles of Epigenetics in Cardiac Fibroblast Activation and Fibrosis These are not purely academic curiosities. If specific epigenetic marks are what flip a fibroblast from quiet maintenance mode to aggressive scar-building mode, then drugs that reverse those marks might halt fibrosis at its source. Several histone-modifying enzymes and specific non-coding RNAs are already being investigated as drug targets, though clinical translation is still years away.
The mechanical environment ties back into epigenetics as well. Cardiac fibroblasts sense stretch and stiffness through structures on their surface and in their internal skeleton, and these forces can alter gene expression through mechanotransduction pathways that ultimately change epigenetic marks in the nucleus.33PubMed Central. The Soft- and Hard-Heartedness of Cardiac Fibroblasts: Mechanotransduction Signaling Pathways in Fibrosis of the Heart In a diseased heart that is already stiff, this creates a feedback loop: stiffness activates fibroblasts, which deposit more collagen, which makes the tissue stiffer, which activates more fibroblasts. Breaking that cycle at the epigenetic level is one of the more promising, if still speculative, ideas in the field.
Embryonic Origins and Why They Matter
For a long time, cardiac fibroblasts were assumed to originate from a single embryonic source. More recent developmental studies have revealed at least two distinct embryonic origins, a finding that may explain why fibroblasts in different regions of the adult heart behave differently.34PubMed Central. Developmental Pathways of Cardiac Fibroblasts If fibroblasts with different developmental lineages have different propensities for activation and collagen production, then the regional variation in fibrosis patterns seen in diseases like hypertrophic cardiomyopathy and ischemic heart disease might partly trace back to their embryonic blueprints. This is still an area where more questions exist than answers, but it has reshaped how researchers think about fibroblast diversity, adding a developmental layer on top of the subpopulation diversity revealed by single-cell sequencing. The practical payoff could come if certain lineage-specific markers prove useful for targeting anti-fibrotic therapies to the fibroblasts most responsible for pathological scarring, while leaving beneficial populations intact.